Canadian HIV & Viral Hepatitis Pharmacists Network (CHAP) Activities
Group Communication
Use this email for group communication and clinical sharing sessions:
This list is open to the general membership of CHAP, and includes pharmacists who are actively interested in HIV pharmacology and/or practice. This group is a restricted list, which means that new members are added by the moderator (Chair). If there are new members who would like to join, they should e-mail the Chair at: chap@hivclinic.ca with a request and a brief bio sketch.
CHAP Chats
CHAP Chats are 1 hour, virtual presentations on timely topics of interest to pharmacists, and are open to all members of CHAP.
| November 21, 2025 | Novel treatment options for TB preventative treatment in people with HIV (J. White) | Passcode: Aj$?A1K@ slides |
| May 23, 2025 | Antiretroviral Therapeutic Drug Monitoring – when to do it? (N. Sheehan) | Passcode: qM?%7g2q |
| October 25, 2024 | Fall Respiratory Vaccine Update (T. Ramsey) | Passcode n7c*8pWR |
| 2023 | Hepatitis C: it can still be challenging (J. Feld) Infant feeding in HIV (S. Khan) | |
| 2022 | A pharmacist’s guide to the use of dual-therapy regimens for HIV infection (CCCEP#: 1329-2022-3369-I-P) (S. Campbell) | |
| 2021 | Antiretroviral resistance: cases (S. Shafran) COVID vaccines and variants (A. Sharkawy) HIV and aging (S. Walmsley) HIV and pediatrics (J. Brophy) HCV update (D. Martel) What to do about M184V? (C. Brumme); Resistance case (L. Akagi) Antiretrovirals in Pregnancy (K. Tulloch); Overview of Women-Centred HIV Care Toolkits (M. Loutfy & M. Ndung’u) |
CHAP National Clinical Observership Program
This program supports 3-4 observerships per year, based on available funds. Canadian CHAP members may apply for a 2-4 day observership to enhance clinical skills and expertise through clinical shadowing/teaching with an experienced HIV pharmacy practitioner at an established practice site. This program is open to new pharmacists entering the area of HIV practice, as well as experienced CHAP members who wish to gain experience in a new clinical area/skill/program. Logistical costs of the program are supported via Sponsorship with Gilead Sciences Canada. Observership applicants and members of the Observership Working Group do not receive any honoraria/consulting fees for their time developing/administering this project.
CHAP Endorsements
CHAP endorsement indicates overall support for an initiative or guideline that is evidence-based, reasonable, and does not contradict CHAP’s mission and values. CHAP is proud to endorse the following guidelines and recommendations:
- Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1. Sherman E et al. Pharmacother 2024;44:488-493.
- Canadian Pediatric & Perinatal HIV/AIDS Research Group consensus recommendations for infant feeding in the HIV context. Khan S et al. J Assoc Med Microbiol Infect Dis Can 2023;8:7-17.
- Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. Tan DHS et al. CMAJ 2017;189:E1448-58.
- ASHP guidelines on pharmacist involvement in HIV care. Schafer JJ et al. Am J Health-Syst Pharm 2016;73:468-94.
Professional Advocacy
CHAP has a long history of professional advocacy. In 2000, CHAP, along with the Society of Infectious Diseases Pharmacists, the American Society of Health-Systems Pharmacists, and the American College of Clinical Pharmacy, submitted a formal letter of protest to the Retrovirus Conference planning committee regarding the selective exclusion of pharmacist registrants to the Retrovirus conference. These collaborative efforts resulted in subsequent modification of pharmacist registration criteria for this prestigious annual meeting.
In 2017, CHAP issued a position statement on Universal Access to Antiretrovirals in Canada. In 2025, CHAP released a position statement supporting Access to care, evidence-based uncensored science, and equity and inclusion of all communities impacted by HIV and/or viral hepatitis. CHAP also submitted a letter to the Office of AIDS Research meeting on June 26, 2025 to advocate for the continued support of the HHS HIV Guidelines by the NIH.
Goals:
To promote cross-country sharing of experiences and information to improve patient care.
To develop practical, clinical guidelines on the role of the pharmacist in caring for patients with HIV and/or viral hepatitis.
To collaborate on research protocols which demonstrate positive drug-related outcomes.
To share continuing education resources, in order to make information on HIV and/or viral hepatitis drug therapy more accessible to community, hospital and ambulatory pharmacists, as well as patients.
To foster the development of HIV and/or viral hepatitis pharmacist mentors.
To promote the pharmacists role in HIV and/or viral hepatitis therapeutics on a national level.